Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00196378 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy
A Phase 3 study, sponsored by Duramed Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00196378 is a Phase 3 study that has completed, run by Duramed Research. The registered enrollment target is 300 participants.
The verdict
NCT00196378, a Phase 3 study, has completed, sponsored by Duramed Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
This is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of Enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal women with or without a hysterectomy and/or oophorectomy.
Interventions
- OTHER Placebo
- DRUG Synthetic Conjugated estrogens, B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00196378
The ClinicalTrials.gov registry entry for NCT00196378 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duramed Research, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00196378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00196378 about?
NCT00196378 is a clinical study titled "A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy". This is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of Enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal women with or without a hysterectomy and/or oophorectomy.
What is the current status of trial NCT00196378?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-11. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00196378?
The interventions under investigation include: Placebo (OTHER), Synthetic Conjugated estrogens, B (DRUG).
Who is sponsoring clinical trial NCT00196378?
This trial is sponsored by Duramed Research, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.